JP2005533073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533073A5 JP2005533073A5 JP2004514661A JP2004514661A JP2005533073A5 JP 2005533073 A5 JP2005533073 A5 JP 2005533073A5 JP 2004514661 A JP2004514661 A JP 2004514661A JP 2004514661 A JP2004514661 A JP 2004514661A JP 2005533073 A5 JP2005533073 A5 JP 2005533073A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- cooh
- conh
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 94
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052731 fluorine Inorganic materials 0.000 claims 20
- 239000000556 agonist Substances 0.000 claims 16
- 229910052794 bromium Inorganic materials 0.000 claims 15
- 229910052801 chlorine Inorganic materials 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 229910052740 iodine Inorganic materials 0.000 claims 10
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 10
- -1 (phenyl) - Chemical class 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- JKDBMAIOGLTQIY-UHFFFAOYSA-N 2-[4-[4-[1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]phenoxy]butyl-methylamino]ethanesulfonic acid Chemical compound C1=CC(OCCCCN(C)CCS(O)(=O)=O)=CC=C1C1N(C=2C=CC(F)=CC=2)C(=O)C1CCC(O)C1=CC=C(F)C=C1 JKDBMAIOGLTQIY-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 230000037356 lipid metabolism Effects 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 102000004146 ATP citrate synthases Human genes 0.000 claims 1
- 108090000662 ATP citrate synthases Proteins 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 102000013585 Bombesin Human genes 0.000 claims 1
- 108010051479 Bombesin Proteins 0.000 claims 1
- 102000019432 Galanin Human genes 0.000 claims 1
- 101800002068 Galanin Proteins 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 1
- 229940086609 Lipase inhibitor Drugs 0.000 claims 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims 1
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 229940122014 Lyase inhibitor Drugs 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 claims 1
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 claims 1
- 102000005630 Urocortins Human genes 0.000 claims 1
- 108010059705 Urocortins Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 239000003392 amylase inhibitor Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 239000002697 lyase inhibitor Substances 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 1
- 239000002658 neuropeptide Y receptor agonist Substances 0.000 claims 1
- 230000002474 noradrenergic effect Effects 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 230000002295 serotoninergic effect Effects 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 125000000542 sulfonic acid group Chemical group 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 239000000777 urocortin Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10227508A DE10227508A1 (de) | 2002-06-19 | 2002-06-19 | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| PCT/EP2003/005816 WO2004000805A1 (de) | 2002-06-19 | 2003-06-04 | Säuregruppen-substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533073A JP2005533073A (ja) | 2005-11-04 |
| JP2005533073A5 true JP2005533073A5 (enExample) | 2006-07-13 |
Family
ID=29719283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004514661A Abandoned JP2005533073A (ja) | 2002-06-19 | 2003-06-04 | 酸性基によって置換されたジフェニルアゼチジノン、その製造方法、該化合物を含む医薬およびそれらの使用 |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1517891B1 (enExample) |
| JP (1) | JP2005533073A (enExample) |
| KR (1) | KR20050008835A (enExample) |
| CN (1) | CN100467448C (enExample) |
| AR (1) | AR039690A1 (enExample) |
| AU (1) | AU2003238210B2 (enExample) |
| BR (1) | BR0311896A (enExample) |
| CA (1) | CA2490112A1 (enExample) |
| DE (1) | DE10227508A1 (enExample) |
| EC (1) | ECSP045497A (enExample) |
| HN (1) | HN2003000185A (enExample) |
| HR (1) | HRPK20041201B3 (enExample) |
| IL (1) | IL165789A0 (enExample) |
| MA (1) | MA27206A1 (enExample) |
| MX (1) | MXPA04012093A (enExample) |
| NO (1) | NO20050134L (enExample) |
| OA (1) | OA12869A (enExample) |
| PA (1) | PA8576101A1 (enExample) |
| PE (1) | PE20040564A1 (enExample) |
| PL (1) | PL372700A1 (enExample) |
| RS (1) | RS108404A (enExample) |
| RU (1) | RU2287522C2 (enExample) |
| SV (1) | SV2004001548A (enExample) |
| TN (1) | TNSN04250A1 (enExample) |
| TW (1) | TW200413311A (enExample) |
| UA (1) | UA78577C2 (enExample) |
| UY (1) | UY27853A1 (enExample) |
| WO (1) | WO2004000805A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| ATE485267T1 (de) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
| US7700597B2 (en) | 2004-12-03 | 2010-04-20 | Schering Corporation | Substituted piperazines as CB1 antagonists |
| BRPI0609614A2 (pt) * | 2005-04-04 | 2010-04-20 | Univ Pontificia Catolica Chile | uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar |
| DE602006010870D1 (de) | 2005-06-20 | 2010-01-14 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| CA2655604C (en) * | 2006-06-23 | 2016-08-09 | Abbott Laboratories | Cyclopropyl amine derivatives |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| DE102007002260A1 (de) | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN101200443B (zh) * | 2007-10-17 | 2011-06-29 | 中国药科大学 | 氮杂环丁酮衍生物、其制备方法及含有它们的药物组合 |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| WO2010100255A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
| CN101993403B (zh) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| BR112021002207A2 (pt) | 2018-08-10 | 2021-05-04 | Diapin Therapeutics, Llc | tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| DE10042447A1 (de) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
| CA2431995A1 (en) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Deutschland Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| IL156550A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
-
2002
- 2002-06-19 DE DE10227508A patent/DE10227508A1/de not_active Withdrawn
-
2003
- 2003-04-06 UA UAA200500488A patent/UA78577C2/uk unknown
- 2003-06-02 SV SV2003001548A patent/SV2004001548A/es not_active Application Discontinuation
- 2003-06-04 CN CNB038143321A patent/CN100467448C/zh not_active Expired - Fee Related
- 2003-06-04 BR BR0311896-7A patent/BR0311896A/pt not_active IP Right Cessation
- 2003-06-04 EP EP03735535A patent/EP1517891B1/de not_active Expired - Lifetime
- 2003-06-04 CA CA002490112A patent/CA2490112A1/en not_active Abandoned
- 2003-06-04 RU RU2005101093/04A patent/RU2287522C2/ru not_active IP Right Cessation
- 2003-06-04 PL PL03372700A patent/PL372700A1/xx not_active Application Discontinuation
- 2003-06-04 RS YUP-1084/04A patent/RS108404A/sr unknown
- 2003-06-04 KR KR10-2004-7020643A patent/KR20050008835A/ko not_active Ceased
- 2003-06-04 JP JP2004514661A patent/JP2005533073A/ja not_active Abandoned
- 2003-06-04 AU AU2003238210A patent/AU2003238210B2/en not_active Ceased
- 2003-06-04 MX MXPA04012093A patent/MXPA04012093A/es active IP Right Grant
- 2003-06-04 OA OA1200400331A patent/OA12869A/en unknown
- 2003-06-04 HR HR20041201A patent/HRPK20041201B3/xx not_active IP Right Cessation
- 2003-06-04 WO PCT/EP2003/005816 patent/WO2004000805A1/de not_active Ceased
- 2003-06-16 PE PE2003000596A patent/PE20040564A1/es not_active Application Discontinuation
- 2003-06-16 UY UY27853A patent/UY27853A1/es unknown
- 2003-06-17 AR ARP030102144A patent/AR039690A1/es unknown
- 2003-06-17 HN HN2003000185A patent/HN2003000185A/es unknown
- 2003-06-17 TW TW092116321A patent/TW200413311A/zh unknown
- 2003-06-18 PA PA20038576101A patent/PA8576101A1/es unknown
-
2004
- 2004-11-16 MA MA27954A patent/MA27206A1/fr unknown
- 2004-12-15 IL IL16578904A patent/IL165789A0/xx unknown
- 2004-12-16 TN TNP2004000250A patent/TNSN04250A1/en unknown
- 2004-12-16 EC EC2004005497A patent/ECSP045497A/es unknown
-
2005
- 2005-01-11 NO NO20050134A patent/NO20050134L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533071A5 (enExample) | ||
| JP2004516293A5 (enExample) | ||
| JP2005533072A5 (enExample) | ||
| JP2006502247A5 (enExample) | ||
| JP2008524127A5 (enExample) | ||
| RU2005101093A (ru) | Замещенные кислотными группами дифенилазетидиноны, способ их получения, содержащие эти соединения лекарственных средства, и их применение | |
| JP2014051526A5 (enExample) | ||
| JP2005523310A5 (enExample) | ||
| FR2840897A1 (fr) | Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique | |
| ME02675B (me) | Novi derivati cikloheksilamina sa aktivnostima beta2 adrenergijskog agonista i m3 muscarinskog antagonista | |
| JP2010533727A5 (enExample) | ||
| JP2012521429A5 (enExample) | ||
| JP2004521924A5 (enExample) | ||
| ATE508113T1 (de) | Indolinverbindung und verfahren zu deren herstellung | |
| RU2005101088A (ru) | Катионозамещенные дифенилазетидиноны, способ их получения, лекарственные средства, содержащие эти соединения, и их применение | |
| JP2006528986A5 (enExample) | ||
| JP2012508252A5 (enExample) | ||
| RU2011129229A (ru) | Новые соли | |
| RU2013127155A (ru) | Новые замещенные бициклические ароматические соединения в качестве ингибиторов s-нитрозоглутатион-редуктазы | |
| JP2005532402A5 (enExample) | ||
| JP2006501201A5 (enExample) | ||
| UY29862A1 (es) | Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2 | |
| RU2401267C2 (ru) | Замещенные производные бензохинолизина | |
| ATE388939T1 (de) | N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor | |
| JP2006523626A5 (enExample) |